It has been announced on Tuesday that the Cycling Anti-Doping Foundation recorded no adverse analytical findings from anti-doping tests conducted during the 2014 edition of the Tour de France.

The total number of 719 blood and urine samples were taken to analysis, including 517 samples being part of the biological passport programme and 197 samples taken before the race has started without a single positive result coming out of them.

“Once again the collaboration with the French Anti-Doping Agency (AFLD) was excellent," Rossi said. "The anti-doping target testing strategy was discussed daily, taking into account the performances of the riders and other data. We also had a valuable contribution from UK Anti-Doping before the start and during all stages in England.

“This year’s Tour was also the first time, in addition to the pre-competition testing, that we organized a second large-scale unannounced mission where all the riders were simultaneously tested for the Athlete Biological Passport during a rest day in Carcassonne. This was made possible thanks to the logistical support of the AFLD,” Rossi said..

“The UCI/CADF took a proactive approach in running an intelligence-led anti-doping programme at this year’s Tour de France and, as with any such operation, UKAD was able to share appropriate information and expertise. Collaborative approaches represent the future of anti-doping.”

The UCI, CADF and AFLD have agreed to store the samples collected for possible retrospective analysis in the future.